Ph.D. Psychology, University of Kentucky
M.A. Psychology, Unidersity of Kentucky
B.A. Psychology, Davidson College
During 2016, Dr. Stoops continued work as principal investigator on three NIDA-funded grants (R21 DA 034095, R01 DA 036553 and R21 DA 035376). One of those grants, R21 DA 034095, was successfully completed. Dr. Stoops served as a co-Investigator or consultant on thirteen other NIH-funded grants, including the newly refunded University of Kentucky Center for Clinical and Translational Science (CCTS). He published eleven peer-reviewed manuscripts, six as first or senior author, in 2016. He presented his research at the College on Problems of Drug Dependence and the American Psychological Association. Dr. Stoops continued his role as Director of the Regulatory Knowledge and Support Core and took on the role of Component Lead for Research Methods of the UK CCTS, adding oversight of the Biostatistics, Epidemiology and Research Design Core to his leadership duties in this center. Dr. Stoops contributed to the teaching mission of the University of Kentucky in 2016 by serving as the primary mentor to one graduate student, one medical student and two undergraduate students. He co-mentored three post-doctoral fellows and one graduate student. Dr. Stoops maintained his high commitment to service to the field at a national level in 2016, including 1) serving on the Board of Convention Affairs of the American Psychological Association, 2) serving as Program Chair of the College on Problems of Drug Dependence, 3) serving on the Board of Directors of the College on Problems of Drug Dependence, 4) serving on the Interventions to Prevent and Treat Addiction NIH study section and 5) being appointed as incoming editor of Experimental and Clinical Psychopharmacology. In 2016, Dr. Stoops was honored to be named the “Psychologist of the Year” by the Kentucky Psychological Association for advancing psychology through excellence in research, teaching, administration and service.
A Human Laboratory Study of n-Acetylcysteine for Alcohol Use Disorder (R21AA026129). National Institute on Alcohol Abuse and Alcoholism.
Selective Monoamine Release as a Treatment for Cocaine Use Disorders (R01DA036553). National Institute on Drug Abuse.
Cardiovascular, Immune and Psychosocial Benefits of Reduced Cocaine Use (R01DA043938). National Institute on Drug Abuse.
Motivation for Cocaine and Non-Drug Reinforcers: Targeting Glutamate Homeostasis (R21DA035376). National Institute on Drug Abuse.
Stoops, W.W., Strickland, J.C., Hays, L.R., Rayapati, A.O., Lile, J.A. and Rush, C.R. (2016). Safety and Tolerability of Intranasal Cocaine During Phendimetrazine Maintenance. Psychopharmacology, 233, 2055-2063.
Strickland, J.C., Bolin, B.L., Lile, J.A., Rush, C.R. and Stoops, W.W. (2016). Differential Sensitivity in Learning from Positive and Negative Outcomes in Cocaine Users. Drug and Alcohol Dependence, 166, 61-68.
Bolin, B.L., Alcorn III, J.L., Lile, J.A., Rush, C.R., Rayapati, A.O., Hays, L.R. and Stoops, W.W. (2017). n-Acetylcysteine Reduces Cocaine-Cue Attentional Bias and Differentially Alters Cocaine Self-Administration Based on Dosing Order. Drug and Alcohol Dependence, 178, 452-460.
Strickland, J.C., Beckmann, J.S., Rush, C.R. and Stoops, W.W. (2017). A Pilot Study of Loss Aversion for Drug and Non-Drug Commodities in Cocaine Users. Drug and Alcohol Dependence, 180, 223-226.